Florent Gros

Florent Gros is a seasoned professional in the biotechnology and venture capital sectors, currently serving as Venture Partner for the Health Fund II at Earlybird Venture Capital since 2020. Gros is the Chairman and Founder of Geneleon and Amyl Therapeutics, while also holding positions as Board Member at ImCheck Therapeutics and CEO & Founder of Priothera SAS. Additionally, Gros is a Director at Captor Therapeutics SA and Managing Partner at Swissvention Partners GmbH. Prior experience includes a role as CEO & Founder of Handl Therapeutics and various leadership positions at Novartis. Gros holds an MBA from Kaufmann and multiple degrees in Private Law and Biotechnology Engineering, alongside qualifications as a French and European Patent Attorney.